Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

103
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
103
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

140
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
140
Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

139
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
139
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

133
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
133
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

289
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
289
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

322
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
322

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exclusion of RNA-binding domains from G-quadruplex condensates by G-quadruplex ligands.

RSC chemical biology·2026
Same author

Loss of p53 Provokes NF-κB-Dependent Disruption of Nucleolar Cap and Nucleoplasmic Redistribution of Fibrillarin During Nucleolar Stress.

Biomolecules·2026
Same author

Investigation of the physicochemical and functional properties of poly(2-methacryloyloxyethyl phosphorylcholine)-conjugated aptamers.

Biomaterials science·2025
Same author

Phase Separation of RX Repeat Peptides with Nucleic Acids.

Chemistry, an Asian journal·2025
Same author

Heterogeneity of Molecular Crowding and Liquid-Liquid Phase Separation.

Sub-cellular biochemistry·2025
Same author

Three- and four-stranded nucleic acid structures and their ligands.

RSC chemical biology·2025

Related Experiment Video

Updated: Apr 14, 2026

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release
09:11

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Published on: February 13, 2016

10.5K

A mRNA-Responsive G-Quadruplex-Based Drug Release System.

Hidenobu Yaku1, Takashi Murashima2, Daisuke Miyoshi3

  • 1Advanced Research Division, Panasonic Corporation, 3-4 Hikaridai, Seika-cho, Soraku-gun, Kyoto 619-0237, Japan. yaku.hidenobu@jp.panasonic.com.

Sensors (Basel, Switzerland)
|April 24, 2015
PubMed
Summary

Researchers developed G-quadruplex-based drug delivery carriers (GDDCs) that release a telomerase inhibitor upon binding to target mRNA. This targeted delivery system demonstrates responsive drug release for potential therapeutic applications.

More Related Videos

Preparation of Multifunctional Silk-Based Microcapsules Loaded with DNA Plasmids Encoding RNA Aptamers and Riboswitches
10:07

Preparation of Multifunctional Silk-Based Microcapsules Loaded with DNA Plasmids Encoding RNA Aptamers and Riboswitches

Published on: October 8, 2021

1.8K
Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction
03:38

Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction

Published on: October 6, 2022

2.0K

Related Experiment Videos

Last Updated: Apr 14, 2026

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release
09:11

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Published on: February 13, 2016

10.5K
Preparation of Multifunctional Silk-Based Microcapsules Loaded with DNA Plasmids Encoding RNA Aptamers and Riboswitches
10:07

Preparation of Multifunctional Silk-Based Microcapsules Loaded with DNA Plasmids Encoding RNA Aptamers and Riboswitches

Published on: October 8, 2021

1.8K
Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction
03:38

Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction

Published on: October 6, 2022

2.0K

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Molecular Biology

Background:

  • G-quadruplex structures offer unique platforms for molecular recognition and drug delivery.
  • Targeted drug release mechanisms are crucial for enhancing therapeutic efficacy and reducing side effects.

Purpose of the Study:

  • To design and characterize G-quadruplex-based drug delivery carriers (GDDCs) capable of capturing and releasing a telomerase inhibitor in response to a specific mRNA sequence.
  • To demonstrate the responsive drug release mechanism triggered by target mRNA hybridization.

Main Methods:

  • Design of GDDCs with varying loop lengths for hybridization with target mRNA.
  • Circular dichroism (CD) spectroscopy for structural analysis of G-quadruplex formation.
  • Visible absorbance and fluorescence titration experiments to assess drug binding, release, and RNA-induced structural changes.

Main Results:

  • GDDCs successfully formed a (3 + 1) G-quadruplex structure.
  • Drug binding affinity (Ka) to CuAPC ranged from 1.5 × 10^5 to 5.9 × 10^5 M^-1.
  • G-quadruplex unfolding and drug release were observed upon hybridization with target RNA, with high affinity (Ka > 1.0 × 10^8 M^-1).

Conclusions:

  • GDDCs can effectively bind and release an anionic copper(II) phthalocyanine (CuAPC) telomerase inhibitor.
  • The carriers exhibit target-specific RNA binding, leading to G-quadruplex structural transition and subsequent drug release.
  • This study presents a promising strategy for developing smart, responsive drug delivery systems for targeted therapies.